Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Lifesci Capital

Lifesci Capital began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a report published on Wednesday morning,Benzinga reports. The firm issued an outperform rating and a $40.00 target price on the stock.

Separately, Guggenheim initiated coverage on shares of Eloxx Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $43.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Price Performance

Shares of ELOX stock opened at $12.47 on Wednesday. The firm has a 50 day moving average of $17.31. Eloxx Pharmaceuticals has a one year low of $11.42 and a one year high of $17.50. The company has a market capitalization of $8.60 million, a PE ratio of -0.82 and a beta of -1,891.27.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.